Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2026 04:30 ET | Source: Commit Biologics

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

Commit Biologics appoints seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer.
March 10, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
February 26, 2026 07:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics

Boehringer and Sitryx Therapeutics partner to advance autoimmune and inflammatory disease research for more personalized, targeted, data driven treatment.
February 26, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated...
February 24, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
February 19, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
February 10, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...
February 04, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
February 03, 2026 01:00 ET | Source: Pharming Group N.V.

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline (PIDs and PMD) at Investor Day today Feb. 3 at 10:00am EST.
January 29, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...